Laura E. Griffin

Laura E. Griffin

Auto-generated profile, based on publicly available information

Laura E. Griffin

Department of Food Science and Technology, Virginia Tech, Blacksburg, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2014 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
MDMelanie R. Dorenkott
Melanie R. Dorenkott
LGLaura E. Griffin
Laura E. Griffin
KGKatheryn M. Goodrich
Katheryn M. Goodrich
KTKatherine Thompson-Witrick
Katherine Thompson-Witrick
GFGabrielle Fundaro
Gabrielle Fundaro
ANAndrew P. Neilson
Andrew P. Neilson

1 October 2012 in Nutrition Research
Verified
Journal Article
Closed access
KGKatheryn M. Goodrich
Katheryn M. Goodrich
GFGabrielle Fundaro
Gabrielle Fundaro
LGLaura E. Griffin
Laura E. Griffin
AGAr'Quette Grant
Ar'Quette Grant
MHMatthew W. Hulver
Matthew W. Hulver
ANAndrew P. Neilson
Andrew P. Neilson

30 August 2017 in Food & Function
Verified
Journal Article
Closed access
PDF file
LGLaura E. Griffin
Laura E. Griffin
KTKatherine Thompson-Witrick
Katherine Thompson-Witrick
CKCourtney Klotz
Courtney Klotz
MDMelanie R. Dorenkott
Melanie R. Dorenkott
KGKatheryn M. Goodrich
Katheryn M. Goodrich
ANAndrew Neilson
Andrew Neilson
Epidemiological and clinical studies suggest that grapes and grape-derived products may reduce the risk for chronic disease. Grape seed extract specifically has been gaining interest due to its reported ability to prevent weight gain, moderate hyperglycemia, and reduce inflammation. The purpose of this study was to examine the long-term effects of two doses of grape seed extract (10 and 100 mg kg−1 body wt per d in mice) on markers of metabolic syndrome in the context of a moderately high-fat diet. After 12 weeks, the lower dose of grape seed extract was more effective at inhibiting fat gain and improving glucose tolerance and insulin sensitivity. Neither the high fat diet nor grape seed extract altered skeletal muscle substrate metabolism. Most interestingly, when examining the profile of metabolically active microbiota in the mucosa of the small intestine, cecum, and colonic tissue, grape seed extract seemed to have the most dramatic effect on small intestinal tissue, where the population of Firmicutes was lower compared to control groups. This effect was not observed in the cecal or colonic tissues, suggesting that the main alterations to gut microbiota due to flavan-3-ol supplementation occur in the small intestine, which has not been reported previously. These findings suggest that grape seed extract can prevent early changes in glucose tolerance and alter small intestinal gut microbiota, prior to the onset of skeletal muscle metabolic derangements, when grape seed extract is consumed at a low dose in the context of a moderately high fat diet.

25 September 2018 in Food & Function
Verified
Journal Article
Open access
PDF file
CAChris J. Angiletta
Chris J. Angiletta
LGLaura E. Griffin
Laura E. Griffin
CSCortney N. Steele
Cortney N. Steele
DBDavid J. Baer
David J. Baer
JNJanet A. Novotny
Janet A. Novotny
ANAndrew Neilson
Andrew Neilson
The gut microbiome metabolizes choline and carnitine to release trimethylamine (TMA), which subsequently undergoes hepatic conversion to trimethylamine N-oxide (TMAO). Elevated TMAO levels are associated with cardiovascular disease and all-cause mortality risk. Dietary flavanols modulate the composition and function of the gut microbiome. Therefore, the possibility exists that these compounds could reduce intestinal TMA production and lower circulating TMAO. However, this hypothesis has never been tested in humans. A secondary analysis was performed on blood samples from a clinical study in which obese subjects at risk for insulin resistance consumed tea or cocoa flavanols in a randomized crossover design while consuming a controlled diet. These subjects generally had elevated TMAO levels (∼5 μM) compared to levels previously measured in healthy subjects (∼1 μM). None of the interventions significantly altered TMAO levels. Individual variability for choline and carnitine was relatively low. However, TMAO exhibited somewhat greater inter-individual variability. No differences in mean TMAO concentrations observed across interventions were seen based on separating subjects by glycemic status, body mass index (BMI), race, age, or gender. However, subject minimum and maximum values observed across the interventions appeared to be more strongly associated with glycemic status and age than mean values across interventions, suggesting that average TMAO values over time may be less useful than maximum or minimum values as markers of disease risk. Traditional physiological characteristics do not appear to predict TMAO responsiveness to flavanol interventions. However, African-American subjects appeared less responsive compared to non-Hispanic white subjects for both green tea and high cocoa treatments, and female subjects appeared less responsive than males for the high cocoa treatment. The present results suggest that a short-term flavanol intervention does not generally reduce fasting TMAO levels in subjects with elevated circulating TMAO.